Regeneron Pharmaceuticals Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Regeneron Pharmaceuticals Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- New York
- Headquarters city
- Tarrytown
- Headquarters state / province
- New York
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- REGN
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0000872589
- EIN
- 13-3444607
Board of directors
-
Arthur F. Ryan · DirectorSince 2023
-
Bonnie L. Bassler · DirectorSince 2023
-
Christine A. Poon · DirectorSince 2023
-
Craig B. Thompson · DirectorSince 2023
-
David P. Schenkein · DirectorSince 2023
-
George L. Sing · DirectorSince 2023
-
George Yancopoulos · Director · Bd. Co-Chair, President & CSOSince 2023
-
Huda Y. Zoghbi · DirectorSince 2023
-
Joseph L. Goldstein · DirectorSince 2023
-
Kathryn Guarini · DirectorSince 2023
-
Leonard S. Schleifer · Director · Bd. Co-Chair, President & CEOSince 2023
-
Marc Tessier-Lavigne · DirectorSince 2023
-
Michael S. Brown · DirectorSince 2023
-
N. Anthony Coles · DirectorSince 2023
-
P. Roy Vagelos · DirectorSince 2023
Chief executives
Leonard S. Schleifer
· Bd. Co-Chair, President & CEO
Dates unknown
Director election results
Annual meeting of June 12, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
70.1%
-
76.8%
-
79.3%
-
96.0%
-
97.4%
Board connections
5 of this board's directors also sit on 8 other boards.
- via David P. Schenkein and Marc Tessier-Lavigne
- via David P. Schenkein
- via Craig B. Thompson
- via Christine A. Poon
- via David P. Schenkein
- via Christine A. Poon
- via Bonnie L. Bassler
- via Christine A. Poon
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $12,905,523
- 84 sales by 7 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 3, 2026 | McCourt Marion Officer (EVP Commercial) | Open-market sale | −1,131 | $857.39 | $969,708 |
| Sep 2, 2026 | Kathryn Guarini Director | Option exercise | +400 | $719.37 | $287,748 |
| Sep 2, 2026 | McCourt Marion Officer (EVP Commercial) | Open-market sale | −1,215 | $850.00 | $1,032,750 |
| Sep 2, 2026 | Kathryn Guarini Director | Open-market sale | −400 | $850.00 | $340,000 |
| Aug 19, 2026 | LAROSA JOSEPH J Officer (EVP General Counsel and Secret) | Option exercise | +12,282 | $381.92 | $4,690,741 |
| Aug 19, 2026 | LAROSA JOSEPH J Officer (EVP General Counsel and Secret) | Shares withheld for tax | −9,019 | $830.15 | $7,487,123 |
| Aug 18, 2026 | Fenimore Christopher R. Officer (EVP Finance CFO) | Option exercise | +6,283 | $381.92 | $2,399,603 |
| Aug 18, 2026 | Fenimore Christopher R. Officer (EVP Finance CFO) | Shares withheld for tax | −4,599 | $813.47 | $3,741,149 |
| Aug 10, 2026 | Kathryn Guarini Director | Option exercise | +400 | $719.37 | $287,748 |
| Aug 10, 2026 | Huda Y. Zoghbi Director | Option exercise | +800 | $376.69 | $301,352 |
| Aug 10, 2026 | Kathryn Guarini Director | Open-market sale | −400 | $800.00 | $320,000 |
| Aug 10, 2026 | Huda Y. Zoghbi Director | Open-market sale | −800 | $800.00 | $640,000 |
| Jul 2, 2026 | Arthur F. Ryan Director | Open-market sale | −200 | $650.15 | $130,030 |
| May 1, 2026 | Arthur F. Ryan Director | Open-market sale | −5 | $701.76 | $3,509 |
| May 1, 2026 | Arthur F. Ryan Director | Open-market sale | −15 | $702.46 | $10,537 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.